Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with
Contrast Media
/ administration & dosage
Diffusion Magnetic Resonance Imaging
Female
Humans
Liver Neoplasms
/ diagnostic imaging
Male
Middle Aged
Neoplasm Metastasis
Neuroendocrine Tumors
/ diagnostic imaging
Octreotide
/ administration & dosage
Radioisotopes
/ administration & dosage
Receptors, Peptide
/ administration & dosage
Journal
Contrast media & molecular imaging
ISSN: 1555-4317
Titre abrégé: Contrast Media Mol Imaging
Pays: England
ID NLM: 101286760
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
05
2019
accepted:
11
09
2019
entrez:
3
12
2019
pubmed:
4
12
2019
medline:
3
7
2020
Statut:
epublish
Résumé
The purpose of this study was to determine if parameters derived from diffusion-weighted (DW-) and dynamic contrast-enhanced (DCE-) magnetic resonance imaging (MRI) can help to assess early response to peptide receptor radionuclide therapy (PRRT) with
Identifiants
pubmed: 31787860
doi: 10.1155/2019/1517208
pmc: PMC6877975
doi:
Substances chimiques
Contrast Media
0
Radioisotopes
0
Receptors, Peptide
0
90Y-octreotide, DOTA-Tyr(3)-
ABF7OG3FA3
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1517208Informations de copyright
Copyright © 2019 Thomas Weikert et al.
Déclaration de conflit d'intérêts
Markus Klarhöfer is an employee of Siemens Healthcare AG (Switzerland) and declares no conflicts of interest regarding this study. All other authors declare that they have no conflicts of interest.
Références
Ann Surg. 2010 Feb;251(2):307-10
pubmed: 20010089
J Am Coll Surg. 2000 Apr;190(4):432-45
pubmed: 10757381
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Cancer. 1981 Jan 1;47(1):207-14
pubmed: 7459811
Mol Imaging Biol. 2014 Aug;16(4):586-94
pubmed: 24526358
Radiat Oncol. 2011 Jun 08;6:65
pubmed: 21651782
Radiology. 1986 Nov;161(2):401-7
pubmed: 3763909
Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):958-65
pubmed: 12829130
Ann N Y Acad Sci. 2004 Apr;1014:13-27
pubmed: 15153416
J Clin Oncol. 2011 Jun 10;29(17):2416-23
pubmed: 21555692
AJR Am J Roentgenol. 2016 Sep;207(3):W26-32
pubmed: 27303858
J Nat Sci. 2018;4(1):
pubmed: 29527572
J Clin Oncol. 2007 Sep 10;25(26):4104-9
pubmed: 17827460
Eur Radiol. 2014 Feb;24(2):267-76
pubmed: 24081644
Int J Cancer. 2016 Dec 15;139(12):2679-2686
pubmed: 27553864
Cancer. 2015 Apr 15;121(8):1172-86
pubmed: 25274401
AJR Am J Roentgenol. 2007 Apr;188(4):1001-8
pubmed: 17377036
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
Eur J Radiol. 2012 Dec;81(12):3870-6
pubmed: 22944331
Br J Radiol. 2013 Oct;86(1030):20130281
pubmed: 23995873
J Nucl Med. 2002 May;43(5):610-6
pubmed: 11994522
Radiology. 2013 Feb;266(2):502-13
pubmed: 23192780
Cardiovasc Intervent Radiol. 2009 Jul;32(4):638-46
pubmed: 19238482
Eur Radiol. 2017 Sep;27(9):3733-3743
pubmed: 28210799
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Top Magn Reson Imaging. 2016 Oct;25(5):245-254
pubmed: 27748710
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Lancet Oncol. 2007 Jan;8(1):63-74
pubmed: 17196512
Cancer Metastasis Rev. 2015 Dec;34(4):823-42
pubmed: 26433592
Br J Cancer. 2013 Apr 16;108(7):1440-8
pubmed: 23492685
Lancet. 1998 Feb 7;351(9100):417-8
pubmed: 9482300
AJR Am J Roentgenol. 2008 Jan;190(1):67-73
pubmed: 18094295
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):766-73
pubmed: 19019563
Sci Rep. 2016 Oct 20;6:35569
pubmed: 27762331
J Hepatol. 2001 Sep;35(3):421-30
pubmed: 11592607
Radiology. 1988 Aug;168(2):497-505
pubmed: 3393671
Transl Oncol. 2013 Jun 01;6(3):256-64
pubmed: 23730404
Clin Nucl Med. 2013 May;38(5):e226-9
pubmed: 23235482
Eur Radiol. 2009 Nov;19(11):2663-71
pubmed: 19504109
J Magn Reson Imaging. 1999 Sep;10(3):223-32
pubmed: 10508281
Lancet. 2002 Jul 27;360(9329):307-8
pubmed: 12147376